widr

Dasatinib (BMS-354825) is an orally active, ATP-competitive tyrosine kinase inhibitor that targets Src and Bcr-Abl (Ki=16/30 pM), with antitumor activity, used in the treatment of leukemia and lymphoma.

Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.

E7820 (ER68203-00) is an angiogenesis inhibitor by suppressing integrin a2 (a cell adhesion molecule expressed on endothelial cells).

Oxaliplatin (L-OHP) is a DNA alkylating agent and DNA synthesis inhibitor. Oxaliplatin induces cellular autophagy and DNA cross-linking damage, thereby inhibiting DNA replication and transcription and leading to cell death. Oxaliplatin is unstable in chlorine-containing systems; dissolution in saline or PBS is not recommended. A 5% glucose/dextrose solution can be used to prepare the solution for in vivo administration.

WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.

Apoptosis inducer53 is an apoptosis inducer that inhibits the proliferation of human tumor cell lines (A549, HeLa, SW1573, T-47D, WiDr) with a GI50 value of 2.5-9.1 μM. It induces apoptosis in cancer cells and decreases colony formation. Furthermore, Apoptosis inducer53 activates the p38α MAPK signaling pathway and exhibits anti-inflammatory effects. It also shows activity against the protozoan parasite Leishmania donovani. Apoptosis inducer53 is applicable in research related to cancer, infections, and inflammation.

Momordicoside F1 may have antiproliferative activities against MCF-7, WiDr, HEp-2, and Doay human tumor cell lines.